Hudson Bay Capital Management LP Agenus Inc Transaction History

Hudson Bay Capital Management LP

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$2.56 - $5.49 $192,000 - $411,750	-75,000 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$2.69 - $5.25 $201,750 - $393,750	75,000 New	75,000 $204,000
Q4 2019 Feb 12, 2020	SELL	$2.41 - $4.4 $253,050 - $462,000	-105,000 Closed	0 $0
Q3 2019 Nov 13, 2019	SELL	$2.17 - $3.14 $75,950 - $109,900	-35,000 Reduced 25.0%	105,000 $271,000
Q2 2019 Aug 14, 2019	BUY	$2.53 - $3.04 $50,599 - $60,800	20,000 Added 16.67%	140,000 $420,000
Q1 2019 May 15, 2019	SELL	$2.51 - $3.73 $514,549 - $764,650	-205,000 Reduced 63.08%	120,000 $356,000
Q4 2018 Feb 13, 2019	SELL	$1.59 - $2.66 $405,450 - $678,300	-255,000 Reduced 43.97%	325,000 $774,000
Q3 2018 Nov 14, 2018	BUY	$1.59 - $2.42 $127,200 - $193,600	80,000 Added 16.0%	580,000 $1.24 Million
Q2 2018 Aug 13, 2018	BUY	$2.26 - $4.65 $1.13 Million - $2.33 Million	500,000 New	500,000 $1.14 Million
Q1 2018 May 14, 2018	SELL	$3.51 - $6.04 $1.58 Million - $2.72 Million	-450,000 Closed	0 $0
Q4 2017 Feb 12, 2018	BUY	$3.26 - $4.78 $554,200 - $812,600	170,000 Added 60.71%	450,000 $1.47 Million
Q3 2017 Nov 13, 2017	BUY	$3.48 - $4.44 $974,400 - $1.24 Million	280,000	280,000 $1.24 Million

2.07M

Ticker AGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 283,163,008
Market Cap $4.73B
Description
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs co...

Get notified when there are updates to the investment portfolio of Hudson Bay Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Hudson Bay Capital Management LP with notifications on news.